AbCellera Biologics
ABCL
ABCL
142 hedge funds and large institutions have $682M invested in AbCellera Biologics in 2023 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 46 increasing their positions, 36 reducing their positions, and 20 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
3% more funds holding
Funds holding: 138 → 142 (+4)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0.33% less ownership
Funds ownership: 41.48% → 41.15% (-0.33%)
Holders
142
Holding in Top 10
4
Calls
$7.64M
Puts
$2.85M
Top Buyers
| 1 | +$12.3M | |
| 2 | +$10.7M | |
| 3 | +$2.83M | |
| 4 |
Goldman Sachs
New York
|
+$1.95M |
| 5 |
Two Sigma Advisers
New York
|
+$1.66M |
Top Sellers
| 1 | -$12.3M | |
| 2 | -$4.78M | |
| 3 | -$4.26M | |
| 4 |
D.E. Shaw & Co
New York
|
-$2.31M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.31M |